Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome (II) plus capecitabine as first-line maintenance for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600134566Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomecapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600134566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134566.